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Background The extent to which adult height, a biomarker of the interplay of
genetic endowment and early-life experiences, is related to risk of
chronic diseases in adulthood is uncertain.
Methods We calculated hazard ratios (HRs) for height, assessed in incre-
ments of 6.5 cm, using individual–participant data on 174 374
deaths or major non-fatal vascular outcomes recorded among
1 085 949 people in 121 prospective studies.
Results For people born between 1900 and 1960, mean adult height
increased 0.5–1 cm with each successive decade of birth. After
adjustment for age, sex, smoking and year of birth, HRs per 6.5 cm
greater height were 0.97 (95% confidence interval: 0.96–0.99) for
death from any cause, 0.94 (0.93–0.96) for death from vascular
causes, 1.04 (1.03–1.06) for death from cancer and 0.92
(0.90–0.94) for death from other causes. Height was negatively asso-
ciated with death from coronary disease, stroke subtypes, heart fail-
ure, stomach and oral cancers, chronic obstructive pulmonary
disease, mental disorders, liver disease and external causes. In con-
trast, height was positively associated with death from ruptured
aortic aneurysm, pulmonary embolism, melanoma and cancers of
the pancreas, endocrine and nervous systems, ovary, breast,
prostate, colorectum, blood and lung. HRs per 6.5 cm greater
height ranged from 1.26 (1.12–1.42) for risk of melanoma death to
0.84 (0.80–0.89) for risk of death from chronic obstructive pulmon-
ary disease. HRs were not appreciably altered after further adjust-
ment for adiposity, blood pressure, lipids, inflammation biomarkers,
diabetes mellitus, alcohol consumption or socio-economic indicators.
Conclusion Adult height has directionally opposing relationships with risk of
death from several different major causes of chronic diseases.
Keywords Height, cardiovascular disease, cancer, cause-specific mortality,
epidemiological study, meta-analysis
Introduction
Adult height is a widely available biomarker that
reflects the interplay of genetic endowment and
various early-life experiences and exposures (such as
fetal, dietary, social and psychological circum-
stances).1–5 Since the study of height could provide
insights into patterns of shared and differing early
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determinants of major diseases of later life, it should
be informative to compare associations of adult height
with subsequent risk of a wide range of disease out-
comes. Previous large prospective studies have re-
ported positive associations between height and risk
of several organ-specific cancer outcomes6–9 and they
have reported negative associations between height
and risk of subsequent vascular disease outcomes.10–12
However, there have been only a few powerful studies
that have examined height in a standardized manner
in relation to a wide range of common and less
common disease outcomes that include neoplastic,
vascular, respiratory and other conditions.13–15
Furthermore, such studies have typically lacked infor-
mation on a variety of biological and other risk factors
for chronic diseases needed to help determine
whether there are independent relationships between
height and late-onset diseases. We aimed to study
associations between baseline adult height and subse-
quent risk of cause-specific death (as well as major
vascular morbidity) by analysing data from 1 085 949
people in mostly population-based studies who were
at risk for a total of 16.1 million person-years.
Methods
By mid-2012, the Emerging Risk Factors Collaboration
(ERFC) had collated and harmonized individual par-
ticipant data from 130 population-based prospective
studies that have included a total of 2.2 million par-
ticipants monitored during 30 million person-years
at risk for cardiovascular disease outcomes and
cause-specific mortality.16 The initial studies of this
collaboration have reported on lipid, inflammation
and glycaemia biomarkers in relation to major vascu-
lar morbidity and cause-specific death.17–21 In 2009,
the ERFC agreed to extend analyses to anthropomet-
ric markers.22 The current analyses focus on the
121 contributing prospective studies that, in addition
to information on adult height at the initial (base-
line) examination, also had information on age
and sex at entry, did not select participants on the
basis of having previous chronic disease (including
vascular disease), recorded cause-specific mortality
and/or vascular morbidity (i.e. non-fatal myocar-
dial infarction or stroke) using clearly defined criteria,
and accrued 41 year of follow-up. Study details
are presented in Supplementary Table 1, available
as Supplementary data at IJE online; acronyms
are in the Supplementary Appendix, available as
Supplementary data at IJE online. There were
1 085 949 participants who had no known history of
vascular disease (i.e. myocardial infarction, angina or
stroke, as defined in each study) at baseline. For
875 782 (81%) of the participants, height was mea-
sured using standardized protocols; for the remainder,
height was self-reported (Supplementary Table 1,
available as Supplementary data at IJE online).
Overall, 619 984 participants had information on
smoking status, blood pressure, history of diabetes,
body mass index (BMI) and total cholesterol, and
585 084 participants had information on smoking
status and socio-economic indicators. In registering
fatal outcomes, all contributing studies used coding
from the ‘International Classification of Diseases’ to
at least three digits or study-specific classification
systems, and ascertainment was based on death
certificates. Attribution of death refers to the primary
cause (or, in its absence, the underlying cause23)
provided. Of the 121 contributing studies, 80 studies
also involved medical records, autopsy findings and
other supplementary sources to help classify deaths,
78 studies used standard definitions of myocardial
infarction based on World Health Organization
criteria and 59 studies reported diagnosis of strokes
on the basis of typical clinical features and brain ima-
ging and attributed stroke subtype.
Details of the statistical methods have been reported
previously.24 Height was normally distributed and the
pooled within-study standard deviation (SD) was
6.5 cm for both males and females. Following the
example of previous reports from the ERFC,17–22 we
assessed associations of height and fatal or first-
ever non-fatal coronary disease or stroke and cause-
specific mortality, including deaths from vascular
disease, cancer and non-vascular conditions not
attributed to cancer, as well as further subdivisions
of these outcomes (e.g. site-specific cancers; see def-
initions in Supplementary Table 2, available as
Supplementary data at IJE online). All participants
contributed either the first non-fatal outcome or
death during follow-up (i.e. deaths preceded by
non-fatal coronary disease or stroke were not
included in the main analyses), ignoring the few out-
comes occurring before the age of 40 years. Subsidiary
analysis was done for fatal outcomes without censor-
ing of previous non-fatal outcomes. Analyses involved
a two-stage approach with estimates of association
calculated separately within each study before pooling
across studies by random-effects meta-analysis.
Hazard ratios (HRs) were calculated using Cox pro-
portional hazard regression models stratified by sex
and decades of year of birth. The proportional
hazard assumptions were satisfied. For each outcome,
participants were censored if they were lost to
follow-up, experienced another outcome or reached
the study’s end of follow-up. For the six contributing
nested case–control studies within prospective cohorts,
odds ratios were calculated using, where appropriate,
conditional or unconditional logistic regression models,
taking into account relevant matching factors.
To assess the shape of association, study- and
sex-specific HRs calculated within quantiles of base-
line height were pooled on a log scale by multivariate
random-effects meta-analysis and plotted against
mean height within each quantile. To reflect the
amount of information within each group (including
the reference group), 95% confidence intervals (CIs)
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were estimated from variances attributed to the
groups.25 Since associations were approximately simi-
lar in both sexes (see Results section), further ana-
lyses were performed in males and females combined
(parallel analyses were done in each sex separately).
When associations were approximately log-linear, re-
gression coefficients were calculated to estimate the
HRs per 1 SD (i.e. 6.5 cm) greater baseline height.
Unless specified otherwise, HRs were adjusted for
age, sex, year of birth and smoking only (current
smokers vs any other status). To explore potential
biological pathways underlying associations, HRs
were further adjusted for systolic blood pressure,
history of diabetes, BMI, waist circumference,
waist-to-hip ratio, total and high density lipoprotein
cholesterol, triglyceride, C-reactive protein, fibrinogen,
alcohol consumption or socio-economic indicators
(i.e. educational attainment and occupational cat-
egory). We investigated effect modification with
formal tests of interaction, and calculated P-values
for interaction with continuous variables, when
appropriate. Diversity between studies was investi-
gated by grouping studies with recorded character-
istics and meta-regression. In the event of missing
data, we conducted analyses in subsets of participants
with complete information on relevant covariates.
Evidence of heterogeneity was indicated by the I2
statistic.26 We corrected for regression dilution
bias27,28 using serial measurement in 355 391 partici-
pants from 67 cohorts, which used standardized proto-
cols to measure height (mean interval: 5.5 years). We
investigated small study effects. Analyses were carried
out in Stata release 11. The study was approved by the
Cambridgeshire Ethics Review Committee and ana-
lysed independently from its funders.
Results
Among the 1 085 949 participants included, the mean
(SD) age at baseline was 5510 years; 48% were
women (Table 1). Most participants were in Europe
(60%) or North America (33%) (Supplementary
Table 1, available as Supplementary data at IJE
online). Median year of baseline survey was 1986
(interquartile range: 1976–92). Although mean
height varied across studies, SDs were similar across
studies (Supplementary Figure 1, available as
Supplementary data at IJE online). Overall mean
(SD) height was 173 6.5 cm in men and
160 6.5 cm in women. Height was negatively corre-
lated with age at baseline, decreasing by an average of
0.7 cm every 5 years in adulthood (Figure 1A). In con-
trast, mean adulthood height adjusted to a given age
(e.g. 50 years) among these people born between 1900
and 1960 increased across each decade of birth year
by 0.5–1 cm per decade (Figure 1B).
At baseline, there were modest and positive correl-
ations of height with body weight, waist and hip
circumference, but weakly negative correlations with
blood pressure, lipids and inflammation biomarkers
(Supplementary Table 3A and Supplementary
Figure 2, available as Supplementary data at IJE
online). On average, people of white European ancestry
were 8.46 cm taller than East Asians, alcohol drinkers
were 0.64 cm taller than non-drinkers, people without
diabetes were 0.34 cm taller than those with diabetes,
people with more education were 5.09 cm taller than
others and people with office jobs were 1.55 cm taller
than manual workers (Supplementary Table 3B, avail-
able as Supplementary data at IJE online). As would be
expected for a trait that is stable in middle-aged people,
the regression-dilution ratio for adult height, adjusted
for age, sex and year of birth, was close to 1.0, i.e. 0.96
(95% CI: 0.95–0.97) during a mean interval of 6 years.
During 16.1 million person-years at risk (median 11.5
years to first outcome), there was a total of 174 374
deaths or major non-fatal vascular outcomes,
comprising 19 768 non-fatal myocardial infarctions,
26 102 coronary deaths and 161 unspecified coronary
heart disease events; 11 757 non-fatal and 9534 fatal
strokes; 13 345 deaths from other vascular diseases,
49 722 deaths from cancer, 34 527 deaths from other
causes and 9458 deaths of unknown or ill-defined
cause. The overall association of height with death
from any cause was weakly inverse and possibly curvi-
linear (Figure 2).
Height and cardiovascular diseases
There were continuous inverse associations between
baseline height and risk of coronary disease and
stroke across the range of values, with possible
attenuation at higher values (Figure 2 and
Supplementary Figure 3, available as Supplementary
data at IJE online). Associations of baseline height
with vascular outcomes are shown in Figure 3. After
adjustment for age, sex, smoking and birth year, HRs
per 1 SD higher baseline height were 0.93 (0.91–0.94)
for coronary disease, 0.94 (0.90–0.97) for ischaemic
stroke, 0.90 (0.85–0.95) for haemorrhagic stroke,
0.91 (0.84–0.98) for subarachnoid haemorrhage,
0.95 (0.92–0.98) for unclassified stroke and 0.94
(0.89–0.99) for death from heart failure. In contrast,
the corresponding HRs were 1.12 (1.03–1.21) for
pulmonary embolism and 1.12 (1.05–1.20) for
ruptured aortic aneurysm (Figure 3). HRs were not
appreciably altered after additional adjustment for
blood pressure, history of diabetes, lipids, C-reactive
protein, fibrinogen, BMI, waist circumference,
waist-to-hip ratio, alcohol consumption or indicators
of socioeconomic status (Tables 2 and 3). HRs for
coronary disease and stroke appeared to become
more extreme with later decade of birth, but HRs
did not vary materially by age, sex, mean height
levels or other characteristics recorded
(Supplementary Figures 4 and 5, available as
Supplementary data at IJE online). Heterogeneity in
HRs for height was only partly explained by the
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Table 1 Baseline data used in the current analysis
Characteristics No. of studies No. of participants Mean (SD) or %
Height (cm) 121 1 085 949 173 (6.5)/160 (6.5)a
Demographic factors
Age at survey (years) 121 1 085 949 55 (10)
Sex 121 1 085 949
Female 522 257 48%
Male 563 692 52%
Ethnicity 93 549 459
East Asian 39 800 7%
Black 29 895 5%
Other 11 369 2%
White 468 395 85%
Physical measurements
BMI (kg/m2) 121 1 081 839 26.0 (4.1)
Systolic blood pressure (mmHg) 117 840 352 136 (19)
History of diabetes 110 833 766
Yes 39 106 5%
No 794 660 95%
Lipid markers
Total cholesterol (mmol/l) 117 824 332 5.84 (1.13)
Non-HDL cholesterol (mmol/l) 100 452 696 4.48 (1.11)
HDL cholesterol (mmol/l) 100 453 106 1.34 (0.37)
Loge triglyceride (mmol/l) 99 661 385 0.33 (0.52)
Inflammation biomarkers
Loge CRP (mg/l) 49 138 177 0.64 (1.10)
Fibrinogen (mmol/l) 46 201 724 9.28 (2.15)
Lifestyle and socio-economic factors
Smoking status 120 1 010 302
Current 315 789 31%
Not current 694 513 69%
Alcohol status 92 511 895
Current 325 781 64%
Not current 186 114 36%
Level of education reached 61 374 737
Tertiary 106 396 28%
Secondary 187 779 50%
Primary 66 758 18%
No schooling 13 804 4%
Occupation or job 59 360 531
Office 127 181 35%
Not working 90 013 25%
Other 47 468 13%
Manual 95 869 27%
aMean (SD) height in males/mean (SD) height in females.
BMI, body mass index; SD, standard deviation; HDL, high density lipoprotein; CRP, C-reactive protein.
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characteristics recorded (Supplementary Figures 4 and
5, available as Supplementary data at IJE online).
Height and cancer mortality and
non-vascular non-cancer mortality
Height was positively and continuously associated
with total cancer mortality (Figure 2 and
Supplementary Figure 6, available as Supplementary
data at IJE online). As regards site-specific cancers,
height was negatively associated with death from
oral and stomach cancers and was positively asso-
ciated with death from melanoma and cancers of
the pancreas, endocrine and nervous systems, breast,
ovary, prostate, colorectum, blood and lung (Figure
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Figure 1 Mean baseline height within 5-year age bands adjusted for calendar year (A) and differences in baseline height
adjusted to age 50 years across calendar years relative to individuals born before 1910 (B). All analyses were adjusted for
between-study differences in mean height via inclusion of a random intercept term in the multilevel mixed effects model.
Error bars represent the 95% CI
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across age-at-risk groups (Supplementary Figure 7,
available as Supplementary data at IJE online).
Adjustment for several risk factors for chronic disease
did not appreciably alter HRs for cancer death
(Tables 2 and 3). There were no clear associations of
height with death from cancer of the liver, connective
tissue, oesophagus or bladder. For every 6.5 cm
greater height, HRs were 0.84 (0.80–0.89) for death
from chronic obstructive pulmonary disease, 0.89
(0.83–0.96) for death from mental disorders,
0.89 (0.84–0.93) for death from liver disease, 0.96
(0.92–1.00) for death from external causes and 0.96
(0.92–1.00) for death from pneumonia (Figure 4 and
Supplementary Figure 8, available as Supplementary
data at IJE online).
Similar results to those reported here were observed in
a range of subsidiary analyses such as those that re-
stricted attention to participants with measured
(rather than self-reported) height (available on
request); omitted the initial 5-years of follow-up,
current smokers, participants of non-European descent
or with a history of diabetes (Table 3); used fixed effect
models (Supplementary Figure 9, available as
Supplementary data at IJE online) or sex-specific
models (Table 3); used age (rather than time-on-study)
as timescale in regression models (Table 3); included
fatal outcomes without censoring previous non-fatal
outcomes (Supplementary Table 4, available as
Supplementary data at IJE online) or corrected concur-
rently for regression dilution in height and in potential
confounders and mediators (Supplementary Table 5,
available as Supplementary data at IJE online). There
was no evidence of small study effects (Supplementary
Figure 10, available as Supplementary data at IJE
online). In an exploratory between-study (ecological)
analysis, there were no clear associations between
study-level mean height values and age-adjusted inci-
dence rates for coronary heart disease, stroke or cancer
mortality (Supplementary Figure 11, available as
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Figure 2 HRs for coronary heart disease, stroke, cancer mortality and all-cause mortality across quantiles of baseline height
values, among males and females. aIncludes both fatal and non-fatal events. Adjusted study-specific loge HRs were com-
bined by multivariate random-effects meta-analysis. Regression analyses were adjusted for age at baseline and smoking
status (current smokers vs any other status), and stratified by decades of year of birth (<1920, 1920–29, 1930–39, 1940–49,
1950–59, 51960) and, where appropriate, by trial arm. Studies with <5 events of an outcome for each sex were excluded
from the analysis of that particular outcome. Sizes of the data markers are proportional to the inverse of the variance of the
loge HRs. Reference groups are the fifth decile or third quintile in each plot
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Discussion
Our results have demonstrated that, although the risk
of all-cause mortality is 3% lower per 6.5 cm greater
height, disaggregation by cause-specific mortality re-
veals stronger and directionally opposing relationships
with risk of death from several different major causes
of chronic disease. HRs per 6.5 cm greater height
ranged from 1.26 (1.12–1.42) for risk of death from
melanoma to 0.84 (0.80–0.89) for risk of death from
chronic obstructive pulmonary disease. Because the
disease associations of height observed here were
not appreciably altered after adjustment for long-term
smoking, adiposity, inflammation biomarkers, blood
pressure, lipids and diabetes, it reduces the
likelihood that these factors are mediators of the
associations in this study. Hence, the results of our
study suggest that variations in adult height (and, by
implication, the genetic and other determinants of
height) have pleiotropic effects on several major
adult-onset diseases. Furthermore, the current data
demonstrate that mean adult height in developed
countries has increased by 0.5-1 cm per decade for
those born between 1900 and 1960. Hence, although
height is 80–90% heritable,29,30 the increases in height
noted over recent decades have almost certainly been
due to non-genetic factors.
The current results primarily have implications for
understanding disease aetiology rather than for clin-
ical risk prediction. Taller people have a lower risk of
death from coronary disease, stroke subtypes, heart
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Figure 3 HRs for vascular outcomes per 1 SD (6.5 cm) higher baseline height, adjusted for age, sex, smoking and year of
birth. aIncludes both fatal and non-fatal events. bRestricted to studies contributing to both outcomes. Causes of other
vascular deaths are ordered by their strength of association. HRs were adjusted for age at baseline and smoking status
(current smokers vs any other status), and stratified by decades of year of birth (<1920, 1920–29, 1930–39, 1940–49,
1950–59, 51960) and, where appropriate, by sex and trial arm. Studies with <5 events were excluded from the analysis of
that particular outcome. For comparison with previous publications, HRs per 5 cm higher baseline height were 0.96
(0.94–0.97) for all vascular deaths; 0.94 (0.93–0.96) for coronary heart disease and 0.95 (0.93–0.97) for stroke
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pulmonary disease, mental disorders, liver diseases
and external causes. Some of these conditions have
previously been associated with height.5,31–34 The
inverse association between height and coronary dis-
ease has been proposed to be because of taller people
having larger coronary vessel diameters, elevated
insulin-like growth factors, slower heart rate and/or
greater lung capacity.5,15,35,36 Conflicting evidence
exists regarding the magnitude of the association
between adult height and risk of major stroke
subtypes.5 Whereas some studies have reported that
associations of height with haemorrhagic stroke and
ischaemic stroke are of similar magnitude to each
other,37–39 the current more powerful analysis (as
well as some previous prospective studies12,40,41)
reported slightly stronger associations with haemor-
rhagic stroke than ischaemic stroke. The explanation
for this difference is not clear, but, since shorter adult
height is believed to reflect, at least in part, poor
nutrition and/or lower socio-economic circumstances
in childhood, it suggests that haemorrhagic stroke
may be more liable to such determinants than
Table 3 HRs for major outcomes per 1 SD (6.5 cm) higher baseline height, adjusted for age, sex, year of birth and smoking
status
Description of supplementary analysis Outcome No. of events HR (95% CI) I2 (95% CI)
Excluding first 5 years of follow-up Coronary heart diseasea 31 680 0.93 (0.91–0.95) 44 (29–56)
Strokea 13 590 0.93 (0.91–0.96) 47 (32–59)
Cancer mortality 39 346 1.05 (1.04–1.07) 18 (0–38)
Excluding current smokers Coronary heart diseasea 27 290 0.92 (0.90–0.94) 45 (31–56)
Strokea 14 182 0.94 (0.92–0.97) 40 (24–53)
Cancer mortality 29 029 1.04 (1.03–1.06) 11 (0–31)
Lung 3164 1.07 (1.03–1.10) 0 (0–30)
Respiratory disease 5435 0.93 (0.88–0.98) 54 (40–65)
Excluding people with a history of
diabetes
Coronary heart diseasea 40 743 0.92 (0.91–0.94) 44 (29–55)
Strokea 16 197 0.94 (0.91–0.96) 43 (28–55)
Cancer mortality 45 089 1.04 (1.03–1.06) 19 (0–38)
Analysis with age (rather than
time-on-study) as timescale
Coronary heart diseasea 43 204 0.92 (0.91–0.94) 52 (40–61)
Strokea 18 502 0.93 (0.91–0.95) 46 (32–57)
Cancer mortality 47 502 1.04 (1.03–1.06) 22 (0–39)
Excluding non-European descents Coronary heart diseasea 40 743 0.92 (0.91–0.94) 44 (29–55)
Strokea 16 197 0.94 (0.91–0.96) 43 (28–55)
Cancer mortality 45 089 1.04 (1.03–1.06) 19 (0–38)
Restricted to men only Coronary heart diseasea 30 958 0.93 (0.91–0.94) 39 (23–51)
Strokea 10 227 0.93 (0.90–0.95) 34 (16–48)
Cancer mortality 25 875 1.04 (1.03–1.06) 4 (0–26)
All-cause mortality 79 763 0.97 (0.96–0.98) 56 (45–64)
Restricted to women only Coronary heart diseasea 12 236 0.93 (0.90–0.95) 29 (5–46)
Strokea 8235 0.94 (0.91–0.98) 43 (24–57)
Cancer mortality 21 616 1.05 (1.02–1.07) 17 (0–39)
All-cause mortality 56 968 0.97 (0.95–0.99) 59 (48–68)
Adjustment for waist circumference
instead of BMIb
Coronary heart diseasea 6043 0.93 (0.90–0.96) 14 (0–41)
Strokea 4016 0.95 (0.91–1.00) 32 (0–54)
Cancer mortality 4950 1.04 (1.00–1.08) 28 (0–52)
Adjustment for waist-to-hip ratio
instead of BMIb
Coronary heart diseasea 5913 0.95 (0.92–0.98) 5 (0–33)
Strokea 3908 0.97 (0.92–1.02) 37 (5–58)
Cancer mortality 4840 1.05 (1.00–1.09) 30 (0–53)
aIncludes both fatal and non-fatal events.
bAnalyses additionally adjusted for systolic blood pressure, history of diabetes and total cholesterol.
HRs are presented per 1 SD (6.5 cm) higher baseline height. HRs were adjusted for age at baseline and smoking status (current
smokers vs any other status), and stratified by decades of year of birth (<1920, 1920–29, 1930–39, 1940–49, 1950–59, 51960), and,
where appropriate, by sex and trial arm. Studies with <5 events were excluded from the analysis of that particular outcome.
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ischaemic stroke.33,34,42 In contrast, there were posi-
tive associations between adult height and risk of
death from pulmonary embolism, which could be be-
cause of greater propensity to venous thrombosis
owing to greater venous surface area or more
venous valves in taller people,43 and ruptured aortic
aneurysm, which could be because of longer arteries
being more prone to rupture.44
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Figure 4 HRs for cause-specific non-vascular mortality per 1 SD (6.5 cm) higher baseline height, adjusted for age, sex,
smoking and year of birth. With the exception of the classifications ‘Other/Unspecified’, causes of deaths are ordered by
their strength of association. HRs were adjusted for age at baseline and smoking status (current smokers vs any other
status), and stratified by decades of year of birth (<1920, 1920–29, 1930–39, 1940–49, 1950–59, 51960) and, where
appropriate, by sex and trial arm. Studies with <5 events were excluded from the analysis of that particular outcome.
HR for all-cause mortality per 1 SD (6.5 cm) height was 0.97 (0.96–0.99), I2¼ 69% (63–75%) and for unknown or ill-defined
cause was 0.96 (0.93–1.00), I2¼ 45% (27–58%). For comparison with previous publications, HRs per 5 cm higher baseline
height were 1.03 (1.02–1.04) for all cancer deaths and 0.94 (0.92–0.95) for all non-cancer non-vascular deaths
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The current study has confirmed that taller people
are at greater risk of death from several organ-specific
malignancies such as melanoma, cancers of the pan-
creas, breast, ovary, prostate and colorectum.6–9 We
observed a HR of 1.04 for all cancer mortality per
6.5 cm greater height, which was similar to that re-
ported in previous prospective studies.6,9,45 It has been
proposed that because taller people have larger
organs, they have greater numbers of cells at risk of
malignant transformation and/or proliferation.46 For
breast and other hormone-related cancers, it has
been proposed that taller people have
tumour-inducing hormonal and biochemical alter-
ations5,47 and/or genes linked with both skeletal
growth and cancer risk.48 The negative association
we observed between height and death from gastric
cancer is consistent with the known relevance to this
malignancy of Helicobacter pylori infection, acquisition
of which is related to poorer socio-economic circum-
stances in childhood.15,49
Our study of over 1 million adults was powerful,
involved individual participant data, adjusted for
several major risk factors, assessed risk factors serially
in 355 000 participants and studied a wide range of
common and less common disease outcomes in a
standardized manner. Since we analysed only
prospective cohort studies, we minimized potential
biases. The generalizability of our findings is sup-
ported by broadly consistent results across 121
prospective cohorts in 24 countries. Due to the
wide age ranges and periods of recruitment of the
participants in our study, we were able to quantify
the trend toward increasing height in successive
birth cohorts. Nonetheless, residual bias could persist
owing to unmeasured or imprecisely measured
confounding factors (e.g. dietary factors and socio-
economic factors, respectively). Height loss in adult-
hood may be related to development of
co-morbidities, which could generate an association
between height and mortality through reverse caus-
ation. However, sensitivity analyses, excluding the ini-
tial years of the follow-up period or restricting
participants to young ages in which height loss is
less likely to happen, suggest that potential bias
owing to shrinkage was unlikely to change the HRs
substantially. Apart from for coronary disease and
stroke, we studied only fatal outcomes. Future studies
will seek to investigate whether height-related genetic
loci4 are associated with the height-related diseases
identified in this report, and to determine whether
ethnic or geographical variation in genetic make-up
could explain the current results. However, the
scope for the latter explanation has been reduced be-
cause 490% of the participants in this study were of
white European descent. The current study encour-
ages more detailed investigation of specific early-life
exposures5 in relation to adult-onset diseases, encom-
passing risk factors from intra-uterine development,
infancy, childhood and adolescence.
Conclusion
Adult height, which is an indicator of the interplay of
genetic and early-life factors, has directionally oppos-
ing relationships with risk of death from several
different major causes of chronic disease.
Supplementary Data
Supplementary Data are available at IJE online.
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KEY MESSAGES
 We analysed individual data on41 million adults in whom 174 000 relevant deaths or events were
recorded during 16 million person-years at risk.
 We found that whereas adult height is inversely related to risk of death from coronary disease, stroke
subtypes, heart failure, stomach and oral cancers, chronic obstructive pulmonary disease, mental
disorders, liver diseases and external causes, adult height is positively associated with risk of death
from pulmonary embolism, ruptured aortic aneurysm and several organ-specific malignancies, such
as melanoma and cancers of the pancreas, breast, ovary, prostate and colorectum.
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